Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer

Wei, Xiao MD; Schlenkhoff, Carl MD; Schwarz, Bettina MD; Essler, Markus MD; Ahmadzadehfar, Hojjat MD, MSc

doi: 10.1097/RLU.0000000000001763
Interesting Images
Buy

Two castration-resistant prostate cancer patients, both with cerebral and visceral and lymphatic metastases, received multiple cycles of 177Lu-PSMA-617 treatments. The prognosis of both cases is dependent on brain metastases. Between 177Lu-PSMA-617 treatment cycles, local radiotherapy was also applied to the brain metastases. Prior to the combined therapy, all systemic metastases, including cerebral lesions, showed PSMA expression using 68Ga-PSMA PET/CT. Under the combined therapy, all the metastases, particularly the cerebral lesions, showed significant regression in size and PSMA expression over time.

From the Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

Received for publication March 29, 2017; revision accepted June 9, 2017.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Hojjat Ahmadzadehfar, MD, MSc, Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany. E-mail: hojjat.ahmadzadehfar@ukbonn.de; nuclearmedicine@gmail.com.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.